7 RESULTS
COMMENT While the outcome of the trial is disappointing, the study was very important, as it tested an important hypothesis in the field—whether targeting α-synuclein using immunotherapy would be beneficial in PD. This is important because α-synuclein pathology ...
COMMENT In this important study, Kumar and colleagues conducted an impressive amount of rigorous work on the study of different forms and assemblies of alpha-synuclein, a central protein in synucleinopathies. The study is systematic, carefully executed, and ...
COMMENT Neuronal dysfunction is thought to precede cell death in most, if not all, neurodegenerative diseases. However, it is still unclear what are the molecular events triggering neuronal dysfunction. While protein aggregation is a pathological hallmark in AD, ...
COMMENT Our understanding of Lewy pathology has not changed much since 1912, when Fritz Heinrich Lewy first reported the typical types of accumulations in the brains of patients. Since 1997–98, we have focused primarily on the fact that α-synuclein appears to be ...
COMMENT Parkinson’s disease is traditionally known for its characteristic motor features. However, non-motor features such as hyposmia, autonomic dysfunction, REM sleep disturbances, and cognitive impairment are also highly debilitating in a significant fraction ...
COMMENT PD is no longer viewed simply as a movement disorder. Numerous non-motor features, including hyposmia, REM sleep disturbances, autonomic dysfunction, and impaired cognitive function, are now known to be present, and to often appear sequentially as disease ...
COMMENT This study is very interesting, and in line with our own work (Zondler et al., 2014; Miller-Fleming et al., 2014). In particular, I find the deglycase activity extremely relevant, and consistent with our recent work, as we think this process is also ...
